Adegbola Richard A, Secka Ousman, Lahai George, Lloyd-Evans Nellie, Njie Alpha, Usen Stanley, Oluwalana Claire, Obaro Stephen, Weber Martin, Corrah Tumani, Mulholland Kim, McAdam Keith, Greenwood Brian, Milligan Paul J M
Medical Research Council Laboratories, The Gambia.
Lancet. 2005;366(9480):144-50. doi: 10.1016/S0140-6736(05)66788-8.
Routine immunisation of infants in The Gambia with a Haemophilus influenzae type b (Hib) polysaccharide-tetanus toxoid conjugate vaccine began in May, 1997. We investigated the effectiveness of the vaccine when delivered through the expanded programme on immunisation and the effect of national immunisation on incidence of Hib disease.
Surveillance for Hib disease was maintained in the western half of The Gambia using standard methods with an emphasis on meningitis. We estimated vaccine efficacy using the case control method, and vaccine coverage and population denominators for incidence rates using a cluster sample survey. Prevalence of Hib carriage in a sample of 1-2-year old children attending health centres for vaccination was ascertained with oropharyngeal swabs plated onto antiserum agar.
Between May, 1997, and April, 2002, a total of 5984 children were examined for possible Hib infections. 49 children had Hib disease, 36 of whom had meningitis. The annual incidence rates of Hib meningitis before any use of the vaccine (1990-93) dropped from over 200 per 100,000 children aged younger than 1 year to none per 100,000 in 2002, and from 60 to no cases per 100,000 in children younger than 5 years. The prevalence of Hib carriage decreased from 12% to 0.25% (p<0.0001). Two doses of vaccine were needed for direct protection from Hib disease (vaccine efficacy 94%, 95% CI 62-99). Since most children received a protective dose after the age of greatest disease risk, indirect effects were important in reducing disease incidence.
The Gambian Hib immunisation programme reduced the occurrence of Hib disease despite irregular vaccine supply. The effect of the programme in The Gambia has important implications for the introduction of the vaccine into routine immunisation programmes of other developing countries.
1997年5月起,冈比亚开始对婴儿常规接种b型流感嗜血杆菌(Hib)多糖-破伤风类毒素结合疫苗。我们调查了通过扩大免疫规划提供该疫苗的效果以及国家免疫接种对Hib疾病发病率的影响。
在冈比亚西部一半地区采用标准方法对Hib疾病进行监测,重点是脑膜炎。我们使用病例对照法估计疫苗效力,使用整群抽样调查估计疫苗接种覆盖率和发病率的人口分母。通过将咽拭子接种在抗血清琼脂上,确定在保健中心接种疫苗的1-2岁儿童样本中Hib携带率。
1997年5月至2002年4月期间,共检查了5984名儿童是否可能感染Hib。49名儿童患有Hib疾病,其中36名患有脑膜炎。在首次使用疫苗之前(1990-1993年),1岁以下儿童Hib脑膜炎的年发病率从每10万名儿童超过200例降至2002年的每10万名儿童无病例,5岁以下儿童从每10万名儿童60例降至无病例。Hib携带率从12%降至0.25%(p<0.0001)。需要两剂疫苗才能直接预防Hib疾病(疫苗效力94%,95%可信区间为62-99)。由于大多数儿童在疾病风险最高的年龄之后才接受保护剂量,间接影响在降低疾病发病率方面很重要。
尽管疫苗供应不规律,冈比亚的Hib免疫规划仍降低了Hib疾病的发生。该规划在冈比亚的效果对其他发展中国家将该疫苗引入常规免疫规划具有重要意义。